Major Adverse Cardiac Events

Also known as: Major Adverse Cardiac Event

Drug	Drug Name	Drug Description
DB08907	Canagliflozin	A sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage hyperglycemia in type 2 diabetes mellitus (DM). Also used to reduce the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 DM.

Drug	Drug Name	Target	Type
DB08907	Canagliflozin	UDP-glucuronosyltransferase 1-9	enzyme
DB08907	Canagliflozin	UDP-glucuronosyltransferase 2B4	enzyme
DB08907	Canagliflozin	Cytochrome P450 3A4	enzyme
DB08907	Canagliflozin	Sodium/glucose cotransporter 2	target
DB08907	Canagliflozin	P-glycoprotein 1	transporter
DB08907	Canagliflozin	Canalicular multispecific organic anion transporter 1	transporter
DB08907	Canagliflozin	Alpha-1-acid glycoprotein 1	carrier
DB08907	Canagliflozin	ATP-binding cassette sub-family G member 2	transporter

Drug	Drug Name	Phase	Status	Count
DB06228	Rivaroxaban	4	Not Yet Recruiting	1
DB01394	Colchicine	Not Available	Withdrawn	1